RPG Life Sciences Q1 net profit jumps 17% on strong domestic formulations, API growth

Drug firm RPG Life Sciences Ltd on Tuesday (July 28) reported a 17% year-on-year increase in consolidated net profit to ₹30.76 crore for the quarter ended June 30, 2026, compared with ₹26.29 crore a year earlier.

Consolidated revenue from operations rose 16% to ₹195.69 crore, up from ₹168.92 crore in the corresponding quarter last year. Consolidated earnings before interest, tax, depreciation and amortisation (EBITDA) increased 22% to ₹43.29 crore from ₹35.47 crore a year ago, while the EBITDA margin improved to 22.1% from 21.0%.

The company said revenue from operations increased 15.8% year-on-year to ₹195.7 crore, while EBITDA grew 17.9% to ₹48.0 crore. EBITDA margin expanded by 40 basis points to 24.5%, supported by operating discipline despite a challenging external environment.

ALSO READ | RPG Life Sciences sees API rebound driving growth, margins to stay steady

The domestic formulations business grew 14.8% during the quarter, ahead of the 11.6% growth recorded by the Indian pharmaceutical market. The company attributed the performance to key therapy focus, new product introductions and field-force effectiveness.

RPG Life Sciences said it entered the Top 50 Indian pharmaceutical companies in June 2026 and became the fifth-fastest-growing company in the Indian pharmaceutical market.

The international formulations business registered 7.7% growth during the quarter, while the active pharmaceutical ingredients (API) business grew 35.6%, supported by a unit returning to operations.

The company also said its Naprosyn brand recorded 16% growth during the quarter. Key therapy segments, including nephrology and rheumatology, posted double-digit growth.

ALSO READ | RPG Life Sciences Q4 Results: Operating performance strong, base quarter one-off impacts profit

Ashok Nair, Managing Director, RPG Life Sciences Ltd, said, "We have started FY27 on a strong note, continuing our track record of market-beating performance and growth. Our Domestic Formulations business continued to outperform the market and helped the company enter the Top 50 ranking in the Indian Pharma Market, an important milestone in our growth journey.

Going forward, we remain focused on strengthening our international presence through market expansion and new customer onboarding, along with scaling up the API operations that can drive the next wave of growth for us. Backed by a strong balance sheet, healthy profitability and continued investment in talent, we remain confident of sustaining our growth momentum in the long-term."

Shares of RPG Life Sciences Ltd ended at ₹2,895.95, down by ₹22.60, or 0.77%, on the BSE.

ALSO READ | RPG Life targets ₹100 crore sales from pain relief drug Naprosyn over the next two years